Latest news with #AmeeraShah
&w=3840&q=100)
Business Standard
18 hours ago
- Business
- Business Standard
Luma Fertility raises $4 mn in seed funding led by Peak XV's Surge
Mumbai-based fertility health-tech startup Luma Fertility has raised $4 million in seed funding, led by Peak XV's Surge, with participation from Ameera Shah (Metropolis Healthcare) and Vijay Taparia (B2V Ventures). The funding will help Luma expand its footprint in Mumbai and later scale into subsequent cities over the next two years. Ameera Shah, promoter and executive chairperson of Metropolis Healthcare, said, 'Fertility care in India is at an inflection point. Demand is growing rapidly, but the system is deeply fragmented and outdated. Patients are forced to navigate a maze of clinics, labs, and specialists with little coordination or support.' Founded by Neha K. Motwani, Luma Fertility's 6,000-square-foot facility houses a lab and offers comprehensive in-house fertility procedures. Luma is the first IVF clinic to launch an integrated app, allowing patients to track their treatment, access reports, and stay informed. Its AI-enabled tool, LumaAI, offers 24/7, jargon-free support on everything from cycle timelines to medication guidance. The global fertility services market is projected to reach $53 billion by 2030, driven by factors such as delayed parenthood, increasing age-related infertility, and declining global fertility rates. In India, the total fertility rate is at a historic low, declining from 2.1 to 1.9 births per woman. Over 33 million couples in the country face fertility challenges, with IVF cycles expected to grow from 320,000 in 2024 to 550,000 by 2028. As India's economy evolves and per capita income rises, there is significant latent demand for transparent, patient-centric, and tech-enabled fertility solutions, including egg and embryo freezing.
Economic Times
a day ago
- Business
- Economic Times
FerTech startup Luma Fertility raises $4 million from Peak XV's Surge fund, others
Mumbai-based fertility-tech startup Luma Fertility has raised $4 million in a round led by Peak XV's Surge platform, which provides seed funding to startups. The round also saw Ameera Shah, executive chairperson of diagnostic company Metropolis Healthcare, and Vijay Taparia, chairman of venture capital firm B2V Ventures, participate. Luma Fertility will use the funds to open more full-stack fertility clinics in Mumbai and expand to other cities over the next two years. 'From my own experience and after speaking to hundreds of women, it became clear that fertility care in India is broken. It's optimised for systems, not people. At Luma, we've rebuilt it from the ground up—designed entirely around the patient,' said Neha K Motwani, the startup's founder, in a prepared statement. Motwani had earlier built fitness marketplace Fitternity, which was acquired by in 2021. Currently, the company has a 6,000 sq ft flagship clinic located in Mumbai's Bandra West. The clinic offers services such as in-vitro fertilisation (IVF), egg and embryo freezing, fertility assessments, and pre-conception consultations. It also has an AI-enabled tool, LumaAI, to assist patients.'Fertility care in India is at an inflection point. Demand is growing rapidly, but the system is deeply fragmented and outdated,' Metropolis Healthcare's Shah said in a statement.B2V Ventures' Taparia, added, 'Having backed Neha in her earlier venture, I've seen firsthand her ability to build with conviction and scale with integrity. Moreover, there is a clear need for consumer-first healthcare in India, especially in single-specialty verticals like fertility.'
Time of India
a day ago
- Business
- Time of India
FerTech startup Luma Fertility raises $4 million from Peak XV's Surge fund, others
Mumbai-based fertility-tech startup Luma Fertility has raised $4 million in a round led by Peak XV's Surge platform, which provides seed funding to round also saw Ameera Shah, executive chairperson of diagnostic company Metropolis Healthcare , and Vijay Taparia, chairman of venture capital firm B2V Ventures, Fertility will use the funds to open more full-stack fertility clinics in Mumbai and expand to other cities over the next two years.'From my own experience and after speaking to hundreds of women, it became clear that fertility care in India is broken. It's optimised for systems, not people. At Luma, we've rebuilt it from the ground up—designed entirely around the patient,' said Neha K Motwani, the startup's founder, in a prepared statement. Motwani had earlier built fitness marketplace Fitternity, which was acquired by in the company has a 6,000 sq ft flagship clinic located in Mumbai's Bandra West. The clinic offers services such as in-vitro fertilisation (IVF), egg and embryo freezing, fertility assessments, and pre-conception consultations. It also has an AI-enabled tool, LumaAI, to assist patients.'Fertility care in India is at an inflection point. Demand is growing rapidly, but the system is deeply fragmented and outdated,' Metropolis Healthcare's Shah said in a statement.B2V Ventures' Taparia, added, 'Having backed Neha in her earlier venture, I've seen firsthand her ability to build with conviction and scale with integrity. Moreover, there is a clear need for consumer-first healthcare in India, especially in single-specialty verticals like fertility.'
Time of India
14-05-2025
- Business
- Time of India
Metropolis Q4 net profit drops 19%, reports no margin gain from Core Diagnostics
Mumbai: Pathology laboratory chain Metropolis Healthcare reported a 19 per cent year-on-year (YoY) decline in net profit to ₹29 crore in the quarter ended March 2025. While the company revenue from operations went up 10 per cent YoY to ₹345 crore, both Profit (8.5 per cent) and adjusted EBITDA margins (24.3 per cent) reflected a dip against the corresponding period. As per the company investors presentation 'the reported EBITDA and PAT (Profit After Tax) were impacted due to one off expenses related to 3 acquisitions, Costs linked to legal and professional fees for tax cases and other small provisions for Inventory.' The company's profit and loss statement that from its total quarterly revenue it incurred a one-time expense of ₹21 crore. During the quarter the company reported 'NIL margin from one if its recent acquisition Core Diagnostics and lower than usual revenue in February in its focus markets.' In December the Pathology chain had acquired 100 per cent stakes of the Delhi-based Core Diagnostics for ₹246 crore. However, the company has maintained a positive outlook for its recent acquisitions. 'We are confident that our recent acquisitions will generate strong returns and fuel the next phase of growth. in specialty testing, expand our B2C footprint, and strengthen our regional presence in North India.' Ameera Shah , Executive Chairperson and Whole-time Director, Metropolis Healthcare Limited, commented. For the full fiscal year the company revenue from operations went up 10 per cent YoY to ₹1,331 crore, while the net profit reported an increase of 14 per cent to ₹146 crore, against the previous fiscal. The current revenue ratio between the company's B2B and B2C services stands at 45:55 and in the last fiscal the two segments reported a YoY increase of 12 per cent and 17 per cent respectively. At the end of FY25 the company portfolio represents 210 clinical labs and is further looking to expand its network. 'With a differentiated portfolio in high-growth segments, and a deeper penetration across key regions, Metropolis is well positioned to capitalize on emerging opportunities and drive long-term stakeholder value,' said Shah. 'As we look ahead, our focus is on strengthening our presence in key cities, expanding digital access, and advancing evidence-based preventive care,' Surendran Chemmenkotil, CEO, Metropolis Healthcare, added.
Business Standard
14-05-2025
- Business
- Business Standard
Metropolis Healthcare slides as Q4 PAT fall 20% YoY to Rs 29 cr
Metropolis Healthcare shares fell 4.42% to Rs 1,626.55 after the company reported a 19.96% decline in consolidated net profit to Rs 29.14 crore for Q4 FY25, compared to Rs 36.41 crore in Q4 FY24. Despite the dip in profit, revenue from operations rose 4.31% year-on-year (YoY) to Rs 345.29 crore for the quarter ended 31 March 2025. Profit before tax fell 28.67% to Rs 36.04 crore in Q4 FY25, compared to Rs 50.53 crore recorded in the same quarter last year. EBITDA increased by 5% YoY to Rs 84 crore, compared to Rs 80 crore in Q4 FY24. However, the EBITDA margin declined to 24.3% in Q4 FY25 from 25.5% in the same quarter last year. The company continued to achieve growth in both patient and test volumes, while strategically reducing its exposure to the low-margin institutional business. Strong B2C growth was driven by infrastructure expansion and a greater focus on wellness services. The B2B segment posted double-digit growth, supported by enhancements in service quality and partner engagement. The TruHealth and Specialty segments emerged as the fastest-growing areas, aligning with the companys strategic focus. TruHealth revenues rose 20% YoY and contributed 19% to total revenues in Q4 FY25. B2C revenue for the quarter grew 14% YoY, with Maharashtra registering a notable 19% YoY increase in this segment. The specialty diagnostics segment posted 11% YoY growth. For FY25, patient volume increased by 6% YoY, while test volume rose by 7%. Revenue per patient also saw robust 6% YoY growth, supported by scientific upselling and micro-market pricing strategies. B2C revenues grew 17% YoY in FY25 and 14% YoY in Q4 FY25, reflecting the companys investments in consumer experience and network expansion. B2B revenue increased 12% YoY in FY25 and 10% YoY in Q4 FY25, driven by enhanced service quality and partner engagement. TruHealth revenues grew 24% YoY in FY25, with a strong Q4 contribution of 19% to total revenue. The specialty diagnostics segment maintained momentum with 13% YoY growth in FY25. Revenue growth from Tier III cities stood at 18% in FY25. The company expanded its reach to over 750 towns, adding 29 new labs and 400 centers during the year, thereby strengthening last-mile access. On a full-year basis, the companys consolidated net profit rose 13.41% to Rs 144.97 crore, on a 10.22% increase in revenue to Rs 1,331.20 crore in FY25 over FY24. Ameera Shah, executive chairperson & whole-time director, Metropolis Healthcare, said, Over the past four years, Metropolis has built a resilient, future-ready organization through strategic investments in laboratories, network expansion, brand, technology, and talent. Despite a challenging environment, we have strengthened our scientific leadership, enhanced customer engagement, and driving operational excellence. We are confident that our recent acquisitions Core Diagnostics, Scientific Pathology, and Dr. Ahujas Pathology & Imaging Centre will generate strong returns and fuel the next phase of growth. These acquisitions reinforce our leadership in specialty testing, expand our B2C footprint, and strengthen our regional presence in North India. With a robust foundation, a differentiated portfolio in high-growth segments, and a deeper penetration across key regions, Metropolis is well positioned to capitalize on emerging opportunities and drive long-term stakeholder value." Surendran Chemmenkotil, chief executive officer, Metropolis Healthcare, said, FY25 has been a pivotal year in our journey toward becoming a more consumer-centric and digitally enabled diagnostics brand. Our growth was fuelled by rising demand for preventive and specialized testing, enabled by focused execution, stronger clinician engagement, and meaningful innovation. We introduced industry-first cancer screening panels and tools, along with AI-powered diagnostics to enhance accuracy and enable early detection. Our proprietary engine, MetAdvisor, uses historical data to deliver personalized, science-led test recommendationsboosting TruHealth performance. As we look ahead, our focus is on strengthening our presence in key cities, expanding digital access, and advancing evidence-based preventive care. With science at the heart of our efforts, we aim to make quality diagnostics more accessible, reliable, and impactful for the communities we serve. Meanwhile, the companys board has approved the re-appointment of Ameera Shah as chairperson and whole-time director of the company for a term of five consecutive years, commencing from 18 March 2026 to 17 March 2031 (both days inclusive), subject to the approval of the shareholders. Further, the board has also approved the appointment of Surendran Chemmenkotil, currently serving as chief executive officer, as an additional director designated as managing director of the company for a term of three consecutive years, commencing from 01 June 2025 to 31 May 2028, subject to shareholder approval. Furthermore, Surendran Chemmenkotil will step down from his position as chief executive officer with effect from the close of business hours on 31 May 2025. Metropolis Healthcare is a diagnostics company with a presence in 22 states, 3 Union Territories, and over 700 towns in India, supported by a robust network of more than 200 laboratories, 4,400 patient service centers, and over 10,000 touchpoints. It offers a comprehensive range of more than 4,000 tests and profiles, including advanced tests for diagnosing cancer, neurological disorders, infectious diseases, and various genetic abnormalities.
